Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 146940
Corporate User License Price USD 6000
Corporate User License Price INR 440820
Site License Price USD 4000
Site License Price INR 293880
Request a Quote

Report Title

Hepatitis D-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hepatitis D-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hepatitis D-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hepatitis D-Pipeline Review, H1 2017



Executive Summary

Hepatitis D-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D-Pipeline Review, H1 2017, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis D-Overview

Hepatitis D-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D-Companies Involved in Therapeutics Development

Alnylam Pharmaceuticals Inc

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Spring Bank Pharmaceuticals Inc

Hepatitis D-Drug Profiles

ALN-HDV-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myrcludex-B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide for Hepatitis D-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-9200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D-Dormant Projects

Hepatitis D-Discontinued Products

Hepatitis D-Product Development Milestones

Featured News & Press Releases

May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection-LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling

Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017

Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting

Apr 04, 2017: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

Feb 20, 2017: Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017

Nov 15, 2016: Replicor Discloses Late Breaking HBV and Follow-Up HBV / HDV Clinical Data at AASLD 2016

Nov 14, 2016: Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting

Oct 19, 2016: Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus Infection

Oct 13, 2016: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting

Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV-4 Study at Hannover Medical School

Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV-3 Study at National Institutes of Health

Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology

May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection

Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B

Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hepatitis D, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hepatitis D, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatitis D-Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Hepatitis D-Pipeline by Eiger BioPharmaceuticals Inc, H1 2017

Hepatitis D-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatitis D-Pipeline by Globeimmune Inc, H1 2017

Hepatitis D-Pipeline by Replicor Inc, H1 2017

Hepatitis D-Pipeline by Rodos BioTarget GmbH, H1 2017

Hepatitis D-Pipeline by SomaGenics Inc, H1 2017

Hepatitis D-Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017

Hepatitis D-Dormant Projects, H1 2017

Hepatitis D-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Alnylam Pharmaceuticals Inc, Eiger BioPharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Globeimmune Inc, Replicor Inc, Rodos BioTarget GmbH, SomaGenics Inc, Spring Bank Pharmaceuticals Inc

Hepatitis D Therapeutic Products under Development, Key Players in Hepatitis D Therapeutics, Hepatitis D Pipeline Overview, Hepatitis D Pipeline, Hepatitis D Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand